CoChat
Sign Up
Cited by 357Metabolism, Diabetes, and CancerCancer, Hypoxia, and MetabolismCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation

Buzzai, Monica, Bauer, Daniel E, Jones, Russell G, DeBerardinis, Ralph J, Hatzivassiliou, Georgia, Elstrom, Rebecca L, Thompson, Craig B·2005·Oncogene
DOI 10.1038/sj.onc.1208622
Open this paper in CoChat — free account

Abstract

Activation of the oncogenic kinase Akt stimulates glucose uptake and metabolism in cancer cells and renders these cells susceptible to death in response to glucose withdrawal. Here we show that 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) reverses the sensitivity of Akt-expressing glioblastoma cells to glucose deprivation. AICAR's protection depends on the activation of AMPK, as expression of a dominant-negative form of AMPK abolished this effect. AMPK is a cellular energy sensor whose activation can both block anabolic pathways such as protein synthesis and activate catabolic reactions such as fatty acid oxidation to maintain cellular bioenergetics. While rapamycin treatment mimicked the effect of AICAR on inhibiting markers of cap-dependent translation, it failed to protect Akt-expressing cells from death upon glucose withdrawal. Compared to control cells, Akt-expressing cells were impaired in the ability to induce fatty acid oxidation in response to glucose deprivation unless stimulated with AICAR. Stimulation of fatty acid oxidation was sufficient to maintain cell survival as activation of fatty acid oxidation with bezafibrate also protected Akt-expressing cells from glucose withdrawal-induced death. Conversely, treatment with a CPT-1 inhibitor to block fatty acid import into mitochondria prevented AICAR from stimulating fatty acid oxidation and promoting cell survival in the absence of glucose. Finally, cell survival did not require reversal of Akt's effects on either protein translation or lipid synthesis as the addition of the cell penetrant oxidizable substrate methyl-pyruvate was sufficient to maintain survival of Akt-expressing cells deprived of glucose. Together, these data suggest that activation of Akt blocks the ability of cancer cells to metabolize nonglycolytic bioenergetic substrates, leading to glucose addiction.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1208622

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 1

  1. Corton JM, Gillespie JG, Hawley SA and Hardie DG . (1995). Eur. J. Biochem., 229, 558–565. · DOI

Cited by

Sorted by citations

Items 301–356 of 356

Related

See all

Metadata

Authors
Buzzai, M., Bauer, D. E., Jones, R. G., DeBerardinis, R. J., Hatzivassiliou, G., Elstrom, R. L., & Thompson, C. B.
Affiliations
  • Abramson Cancer Center (US)
  • Children's Hospital of Philadelphia (US)
Corresponding author
Thompson, Craig B
ORCID
Venue
Oncogene
Publisher
Springer Science and Business Media LLC
Published
2005-04-04
Volume
24
Issue
26
Pages
4165-4173
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
DOI
10.1038/sj.onc.1208622
OpenAlex
W1964353872
Cited by
357
References
29
Citations by year
2025: 8 · 2024: 6 · 2023: 11 · 2022: 11 · 2021: 13 · 2020: 14 · 2019: 27 · 2018: 16 · 2017: 17 · 2016: 19 · 2015: 15 · 2014: 35 · 2013: 23 · 2012: 34
FWCI
5.90
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Damon Runyon Cancer Research Foundation
  • University of Pennsylvania
  • National Institutes of Health
  • National Institute of General Medical Sciences (5T32-GM008638-08, T32GM008638)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
Akt, glucose deprivation, fatty acid beta-oxidation, AMPK, AICAR, glioblastoma, rapamycin, cap-dependent translation, bezafibrate, methyl pyruvate, cancer metabolism, energy sensing, cell survival
MeSH terms
Aminoimidazole Carboxamide, Cell Survival, Fatty Acids, Glioma, Glucose, Humans, Hypoglycemic Agents, Oxidation-Reduction, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Ribonucleotides, Tumor Cells, Cultured, Protein Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review